Caustic Soda Pearls - China CAS: 1310-73-2
Related Insights
EPA's New PFAS Guidance: Impact on Biosolids, Fertilizer, and the Food Chain
The EPA’s updated PFAS guidance reshapes how farmers use biosolids and fertilizers, influencing crop inputs and the broader food ingredient supply chain. Learn what it means for compliance, sourcing, and consumer safety.
Refrigerant R22 Jumps Over 2,000 Yuan per Tonne: Understanding the July 2026 Price Shock
Refrigerant R22 prices surged by more than 2,000 yuan per tonne within a single week during July 2026, drawing attention across China's chemical market. Procurement teams should understand what such rapid movements may signal for refrigerant supply, industrial demand and purchasing strategies.
Steam Cracker Economics: How China's High Utilization Is Squeezing European Petrochemical Producers
Chinese steam crackers operating near maximum capacity can spread fixed costs across larger output volumes and export surplus petrochemicals into global markets. European crackers averaging around 75% utilization face a widening cost disadvantage that could reshape polymer pricing, regional production and procurement strategies
REACH SVHC July 2026 Update: What the ECHA Candidate List Addition Means for Specialty Chemical Supply Chains
The July–August 2026 SVHC update by ECHA is the most significant regulatory change for European chemical buyers this year. Potential additions such as brominated flame retardants, phthalate plasticizers and organotin compounds will trigger immediate compliance obligations. Specialty chemical distributors, manufacturers and importers must act now to avoid regulatory exposure.
Jordan API Supply: Post-Crisis Recovery Assessment for Antibiotic Procurement Teams
Jordan's pharmaceutical API exports are showing signs of recovery as regional shipping conditions improve. Buyers dependent on antibiotic APIs should use July to verify logistics, rebuild inventories and secure Q3 supply agreements. This guide evaluates logistics recovery, procurement risks and outlines actionable Q3 sourcing strategies.
Pharmaceutical Supply Chain: H1 2026 Closing Risk Assessment
The first half of 2026 exposed major vulnerabilities in pharmaceutical supply chains. API concentration, shipping disruptions, and logistics risks are reshaping procurement strategies for H2 2026 and beyond.
Don't miss out on our updates! Subscribe to our newsletter now
We're committed to your privacy. Tradeasia uses the information you provide to us to contact you about our relevant content, products, and services. For more information, check out our privacy policy.